 Eli Lilly & Co. said an experimental, once-weekly drug for Type 2 diabetes was comparable to Novo Nordisk A/S's once-daily Victoza in reducing a measure of blood sugar in a patient study, a finding Lilly hopes will give it a competitive advantage if its drug reaches the market.. Lilly said its long-acting drug, dulaglutide, wasn't superior to Victoza, which had 2013 sales of about $2.1 billion. Lilly disclosed an abbreviated summary of the trial's results in a press release Tuesday, and plans to present full data at a scientific...
  